A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2019-06-10
Target enrollment:
Participant gender:
Summary
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess
safety in pediatric subjects aged 2 to 17 years with atopic dermatitis
Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244
Phase 1b